Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Peihua Lu

Peihua Lu

MD
Lu Daopei Hospital
Anti-CD7 CAR-T therapy for T-ALL/LBL 0:53
Anti-CD7 CAR-T therapy for T-ALL/LBL
Peihua Lu • 9 Dec 2023
AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL 1:15
AlloSCT outcomes in patients who achieve CR with CAR-T versus chemotherapy in T-ALL/LBL
Peihua Lu • 9 Dec 2023
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial 3:16
CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial
Peihua Lu • 9 Dec 2023
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL 2:16
Evaluating the safety and efficacy of novel anti-CD7 universal CAR-T therapy in R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022
Safety and efficacy of CD7-targeted CAR-T therapy in patients with R/R T-ALL and T-LBL 8:37
Safety and efficacy of CD7-targeted CAR-T therapy in patients with R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022
Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALL 5:14
Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALL
Peihua Lu • 16 Jun 2022
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL 5:39
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu • 16 Jun 2022
Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma 3:34
Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma
Peihua Lu • 16 Jun 2022
CD7 gene knockout CAR-T cell therapy for R/R T-cell hematological malignancies 5:29
CD7 gene knockout CAR-T cell therapy for R/R T-cell hematological malignancies
Peihua Lu • 16 Jun 2022
Factors associated with treatment response to CD19 CAR T-cell therapy in B-ALL 3:42
Factors associated with treatment response to CD19 CAR T-cell therapy in B-ALL
Peihua Lu • 4 Nov 2021
Risks and indications for consolidation alloHSCT after CAR T-cell therapy in ALL 4:24
Risks and indications for consolidation alloHSCT after CAR T-cell therapy in ALL
Peihua Lu • 4 Nov 2021
Benefits of post CAR-T alloHSCT consolidation therapy in B-ALL 2:51
Benefits of post CAR-T alloHSCT consolidation therapy in B-ALL
Peihua Lu • 4 Nov 2021
CD19/CD20 dual STAR T-cell therapy for R/R B-ALL 3:37
CD19/CD20 dual STAR T-cell therapy for R/R B-ALL
Peihua Lu • 1 Jun 2021
The latest advances in CAR-T therapy for B-ALL 1:59
The latest advances in CAR-T therapy for B-ALL
Peihua Lu • 1 Jun 2021
Where is the researching moving in CAR-T? 1:20
Where is the researching moving in CAR-T?
Peihua Lu • 1 Jun 2021
Considerations and challenges of integrating CAR-T and transplantation in B-ALL 3:56
Considerations and challenges of integrating CAR-T and transplantation in B-ALL
Peihua Lu • 1 Jun 2021
The content of VJHemOnc is intended for healthcare professionals